{"topic":{"slug":"cancer-immunotherapy","name":"Cancer Immunotherapy","domain":"medicine","description":"Immune checkpoint inhibitors, CAR-T and TIL cell therapies including solid tumors, T-cell engagers and bispecifics, and antibody-drug conjugates.","keywords":["immunotherapy","CAR-T","checkpoint inhibitor"],"paper_count":288,"latest_published":"2026-10-27","url":"https://space-kitty.com/topics/cancer-immunotherapy","api_url":"https://space-kitty.com/api/v1/topics/cancer-immunotherapy"},"dossier":null,"top_papers":[{"id":"doi:10.1159/000455014","kind":"review","title":"Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review","authors":["Rimda Wanchoo","Sabine Karam","Nupur N. Uppal","Valerie S. Barta","Gilbert Deray","Craig Devoe"],"author_count":9,"year":2017,"published":"2017-01-01","venue":"American Journal of Nephrology","cited_by":15256,"doi":"10.1159/000455014","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.1159/000455014","archive_url":"https://space-kitty.com/papers/doi:10.1159/000455014"},{"id":"doi:10.1038/s41572-020-00240-3","kind":"review","title":"Hepatocellular carcinoma","authors":["Josep Maria Llovet","Robin Kate Kelley","Augusto Villanueva","Amit G. Singal","Eli Pikarsky","Sasan Roayaie"],"author_count":10,"year":2021,"published":"2021-01-21","venue":"Nature Reviews Disease Primers","cited_by":7050,"doi":"10.1038/s41572-020-00240-3","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.1038/s41572-020-00240-3","archive_url":"https://space-kitty.com/papers/doi:10.1038/s41572-020-00240-3"},{"id":"doi:10.1038/s41588-018-0312-8","kind":"article","title":"Tumor mutational load predicts survival after immunotherapy across multiple cancer types","authors":["Robert M. Samstein","Chung‐Han Lee","Alexander Noor Shoushtari","Matthew David Hellmann","Ronglai Shen","Yelena Yuriy Janjigian"],"author_count":57,"year":2019,"published":"2019-01-08","venue":"Nature Genetics","cited_by":4069,"doi":"10.1038/s41588-018-0312-8","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.1038/s41588-018-0312-8","archive_url":"https://space-kitty.com/papers/doi:10.1038/s41588-018-0312-8"},{"id":"doi:10.1186/s13073-017-0424-2","kind":"article","title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","authors":["Zachary Rockow Chalmers","Caitlin F. Connelly","David A. Fabrizio","Laurie M. Gay","Siraj Mahamed Ali","Riley Charles Ennis"],"author_count":24,"year":2017,"published":"2017-04-13","venue":"Genome Medicine","cited_by":3517,"doi":"10.1186/s13073-017-0424-2","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.1186/s13073-017-0424-2","archive_url":"https://space-kitty.com/papers/doi:10.1186/s13073-017-0424-2"},{"id":"doi:10.1038/s41423-020-0488-6","kind":"review","title":"The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications","authors":["Yuanyuan Zhang","Zemin Zhang"],"author_count":2,"year":2020,"published":"2020-07-01","venue":"Cellular and Molecular Immunology","cited_by":2817,"doi":"10.1038/s41423-020-0488-6","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.1038/s41423-020-0488-6","archive_url":"https://space-kitty.com/papers/doi:10.1038/s41423-020-0488-6"},{"id":"doi:10.1038/nrclinonc.2016.66","kind":"review","title":"Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease","authors":["Giampaolo Bianchini","Justin Micah Balko","Ingrid A. Mayer","Melinda E. Sanders","Luca Gianni"],"author_count":5,"year":2016,"published":"2016-05-17","venue":"Nature Reviews Clinical Oncology","cited_by":3073,"doi":"10.1038/nrclinonc.2016.66","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.1038/nrclinonc.2016.66","archive_url":"https://space-kitty.com/papers/doi:10.1038/nrclinonc.2016.66"},{"id":"doi:10.1038/s41392-022-00947-7","kind":"review","title":"Antibody drug conjugate: the \"biological missile\" for targeted cancer therapy","authors":["Fu Z","Li S","Han S","Shi C","Zhang Y"],"author_count":5,"year":2022,"published":"2022-03-22","venue":"Signal transduction and targeted therapy","cited_by":1271,"doi":"10.1038/s41392-022-00947-7","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.1038/s41392-022-00947-7","archive_url":"https://space-kitty.com/papers/doi:10.1038/s41392-022-00947-7"},{"id":"doi:10.1186/s40425-017-0300-z","kind":"article","title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","authors":["on behalf of the Society for Immunotherapy of Cancer Toxicity Management Working Group","Igor J. Puzanov","Adi K. Diab","K. Abdallah","Clifton O. Bingham","Cynthia F. Brogdon"],"author_count":22,"year":2017,"published":"2017-11-21","venue":"Journal for ImmunoTherapy of Cancer","cited_by":1992,"doi":"10.1186/s40425-017-0300-z","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.1186/s40425-017-0300-z","archive_url":"https://space-kitty.com/papers/doi:10.1186/s40425-017-0300-z"},{"id":"doi:10.1038/s12276-018-0191-1","kind":"review","title":"Immune checkpoint inhibitors: recent progress and potential biomarkers","authors":["Darvin P","Toor SM","Sasidharan Nair V","Elkord E"],"author_count":4,"year":2018,"published":"2018-12-13","venue":"Experimental & molecular medicine","cited_by":1602,"doi":"10.1038/s12276-018-0191-1","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.1038/s12276-018-0191-1","archive_url":"https://space-kitty.com/papers/doi:10.1038/s12276-018-0191-1"},{"id":"doi:10.1038/nature23003","kind":"article","title":"Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer","authors":["Uğur Şahin","Evelyna Derhovanessian","Matthias Miller","Björn‐Philipp Kloke","Petra Simon","Martin Löwer"],"author_count":50,"year":2017,"published":"2017-07-04","venue":"Nature","cited_by":2485,"doi":"10.1038/nature23003","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.1038/nature23003","archive_url":"https://space-kitty.com/papers/doi:10.1038/nature23003"},{"id":"doi:10.1038/s41568-019-0116-x","kind":"review","title":"The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy","authors":["Jonathan J. Havel","Diego Chowell","Timothy An-thy Chan"],"author_count":3,"year":2019,"published":"2019-02-12","venue":"Nature reviews. Cancer","cited_by":2285,"doi":"10.1038/s41568-019-0116-x","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.1038/s41568-019-0116-x","archive_url":"https://space-kitty.com/papers/doi:10.1038/s41568-019-0116-x"},{"id":"doi:10.1146/annurev-pathol-042020-042741","kind":"review","title":"Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance","authors":["Sreya Bagchi","Robert T. Yuan","Edgar G. Engleman"],"author_count":3,"year":2020,"published":"2020-11-16","venue":"Annual Review of Pathology Mechanisms of Disease","cited_by":2188,"doi":"10.1146/annurev-pathol-042020-042741","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.1146/annurev-pathol-042020-042741","archive_url":"https://space-kitty.com/papers/doi:10.1146/annurev-pathol-042020-042741"},{"id":"doi:10.1038/s41392-022-01046-3","kind":"review","title":"Autophagy, ferroptosis, pyroptosis, and necroptosis in tumor immunotherapy","authors":["Weitong Gao","Yuqin Wang","Yang Zhou","Xueqian Wang","Yan Yu"],"author_count":5,"year":2022,"published":"2022-06-20","venue":"Signal Transduction and Targeted Therapy","cited_by":1052,"doi":"10.1038/s41392-022-01046-3","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.1038/s41392-022-01046-3","archive_url":"https://space-kitty.com/papers/doi:10.1038/s41392-022-01046-3"},{"id":"doi:10.3390/cancers12030738","kind":"review","title":"Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence","authors":["Raju Kumar Vaddepally","Prakash Kharel","Ramesh Kumar Pandey","Rohan Garje","Abhinav Binod Chandra"],"author_count":5,"year":2020,"published":"2020-03-20","venue":"Cancers","cited_by":1198,"doi":"10.3390/cancers12030738","arxiv_id":null,"nct_id":null,"source_url":"http://dx.doi.org/10.3390/cancers12030738","archive_url":"https://space-kitty.com/papers/doi:10.3390/cancers12030738"},{"id":"doi:10.1038/s41573-022-00520-5","kind":"review","title":"Macrophages as tools and targets in cancer therapy","authors":["Alberto Mantovani","Paola Allavena","Federica Marchesi","Cecília Garlanda"],"author_count":4,"year":2022,"published":"2022-08-16","venue":"Nature Reviews Drug Discovery","cited_by":1806,"doi":"10.1038/s41573-022-00520-5","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.1038/s41573-022-00520-5","archive_url":"https://space-kitty.com/papers/doi:10.1038/s41573-022-00520-5"}],"newest_papers":[{"id":"nct:NCT07897799","kind":"trial","title":"The METAMAX Study: MT027 Allogeneic CAR-T for Brain Metastases From Advanced Solid Tumors","authors":["T-MAXIMUM Pharmaceutical Inc"],"author_count":1,"year":2026,"published":"2026-10-27","venue":"ClinicalTrials.gov","cited_by":null,"doi":null,"arxiv_id":null,"nct_id":"NCT07897799","source_url":"https://clinicaltrials.gov/study/NCT07897799","archive_url":"https://space-kitty.com/papers/nct:NCT07897799"},{"id":"doi:10.1186/s40164-026-00843-8","kind":"article","title":"Blocking aryl hydrocarbon receptor remodels myeloid-T cell crosstalk and enhances anti-PD-1 response in the tumor microenvironment","authors":["Kim DK","Baek S","Kim Y","Yang SM","Park SY","Choi SJ"],"author_count":14,"year":2026,"published":"2026-10-26","venue":"Experimental hematology & oncology","cited_by":0,"doi":"10.1186/s40164-026-00843-8","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.1186/s40164-026-00843-8","archive_url":"https://space-kitty.com/papers/doi:10.1186/s40164-026-00843-8"},{"id":"doi:10.1007/s10072-026-09500-8","kind":"article","title":"Neuronal intermediate filament neurologic autoimmunity in a patient with Merkel cell carcinoma receiving pembrolizumab","authors":["Hijazi A","Guleryuz S","Walshauser MA","Hayat G","Chappidi M"],"author_count":5,"year":2026,"published":"2026-10-23","venue":"Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology","cited_by":0,"doi":"10.1007/s10072-026-09500-8","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.1007/s10072-026-09500-8","archive_url":"https://space-kitty.com/papers/doi:10.1007/s10072-026-09500-8"},{"id":"doi:10.1038/s41467-026-78897-9","kind":"article","title":"Extracorporeal photopheresis for the treatment of steroid-refractory immune related adverse events from immune checkpoint inhibitor therapy: a multi-center phase Ib/II clinical trial","authors":["Riemer R","Braun LM","Giesler S","Rafei-Shamsabadi D","Haferkamp S","Hartmann A"],"author_count":46,"year":2026,"published":"2026-10-23","venue":"Nature communications","cited_by":0,"doi":"10.1038/s41467-026-78897-9","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.1038/s41467-026-78897-9","archive_url":"https://space-kitty.com/papers/doi:10.1038/s41467-026-78897-9"},{"id":"doi:10.1038/s42003-026-11092-0","kind":"article","title":"Dysregulation of the Hippo pathway enhances PD-L2 transcription to promote immune evasion in head and neck squamous cell carcinoma","authors":["Ando T","Okamoto K","Sato K","Goto Y","Izumi H","Kataoka N"],"author_count":18,"year":2026,"published":"2026-10-23","venue":"Communications biology","cited_by":0,"doi":"10.1038/s42003-026-11092-0","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.1038/s42003-026-11092-0","archive_url":"https://space-kitty.com/papers/doi:10.1038/s42003-026-11092-0"},{"id":"doi:10.3390/biotech15040096","kind":"article","title":"Cell-Based Assay Development and Standardization for Antibody-Drug Conjugates","authors":["Sun D","Hsu A","Long H","Qin K","Welch J","McCann S"],"author_count":7,"year":2026,"published":"2026-10-20","venue":"Biotech (Basel (Switzerland))","cited_by":0,"doi":"10.3390/biotech15040096","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.3390/biotech15040096","archive_url":"https://space-kitty.com/papers/doi:10.3390/biotech15040096"},{"id":"doi:10.3390/curroncol33100616","kind":"article","title":"Immune Checkpoint Inhibitor-Associated Pneumonitis in Patients Treated for Metastatic Renal Cell Carcinoma","authors":["Masur J","Mullapudi A","Ali S","Fortune K","Bueno J","Battey T"],"author_count":13,"year":2026,"published":"2026-10-14","venue":"Current oncology (Toronto, Ont.)","cited_by":0,"doi":"10.3390/curroncol33100616","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.3390/curroncol33100616","archive_url":"https://space-kitty.com/papers/doi:10.3390/curroncol33100616"},{"id":"doi:10.3390/medsci14060669","kind":"review","title":"From Dysbiosis to Symbiosis: Using the Gut Microbiome to Improve Cancer Outcomes","authors":["Nassar SA"],"author_count":1,"year":2026,"published":"2026-10-13","venue":"Medical sciences (Basel, Switzerland)","cited_by":0,"doi":"10.3390/medsci14060669","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.3390/medsci14060669","archive_url":"https://space-kitty.com/papers/doi:10.3390/medsci14060669"},{"id":"nct:NCT07865910","kind":"trial","title":"A Study to Learn the Safety and Efficacy of HLX37 in Combination With Chemotherapy for First-line Treatment in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer","authors":["Shanghai Henlius Biotech"],"author_count":1,"year":2026,"published":"2026-10-08","venue":"ClinicalTrials.gov","cited_by":null,"doi":null,"arxiv_id":null,"nct_id":"NCT07865910","source_url":"https://clinicaltrials.gov/study/NCT07865910","archive_url":"https://space-kitty.com/papers/nct:NCT07865910"},{"id":"doi:10.3390/curroncol33100603","kind":"article","title":"Patient-Reported Burden and Clinical Spectrum of Rheumatic Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy in Lung Cancer: A Real-World Cohort Study","authors":["Ren Z","Lu J"],"author_count":2,"year":2026,"published":"2026-10-07","venue":"Current oncology (Toronto, Ont.)","cited_by":0,"doi":"10.3390/curroncol33100603","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.3390/curroncol33100603","archive_url":"https://space-kitty.com/papers/doi:10.3390/curroncol33100603"}],"related_topics":[{"slug":"mrna-cancer-vaccines","name":"mRNA Therapeutics & Cancer Vaccines","api_url":"https://space-kitty.com/api/v1/topics/mrna-cancer-vaccines"},{"slug":"gene-editing-therapies","name":"CRISPR & Gene-Editing Therapies","api_url":"https://space-kitty.com/api/v1/topics/gene-editing-therapies"},{"slug":"gene-cell-therapy","name":"Gene & Cell Therapy","api_url":"https://space-kitty.com/api/v1/topics/gene-cell-therapy"},{"slug":"glp1-metabolic","name":"GLP-1 & Incretin Therapies","api_url":"https://space-kitty.com/api/v1/topics/glp1-metabolic"},{"slug":"neurodegeneration","name":"Alzheimer's, Parkinson's & Neurodegeneration","api_url":"https://space-kitty.com/api/v1/topics/neurodegeneration"},{"slug":"aging-longevity","name":"Biology of Aging & Longevity","api_url":"https://space-kitty.com/api/v1/topics/aging-longevity"},{"slug":"infectious-disease-amr","name":"Infectious Disease, Vaccines & Antimicrobial Resistance","api_url":"https://space-kitty.com/api/v1/topics/infectious-disease-amr"},{"slug":"ai-medicine","name":"AI in Clinical Medicine","api_url":"https://space-kitty.com/api/v1/topics/ai-medicine"},{"slug":"cardiovascular-innovation","name":"Cardiovascular Therapeutics","api_url":"https://space-kitty.com/api/v1/topics/cardiovascular-innovation"}],"premium":{"dossier":null,"research_pack":{"url":"https://space-kitty.com/api/v1/topics/cancer-immunotherapy/pack","price_usd":"0.20"}},"more":"https://space-kitty.com/api/v1/topics/cancer-immunotherapy/papers?sort=top&limit=100"}